Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $4.38 per share for the third quarter of 2024, ...

We expect Vertex Pharmaceuticals Incorporated VRTX to surpass expectations when it reports third-quarter 2024 results on Nov.

Analyst Joshua Reilly of Needham maintained a Buy rating on Vertex (VERX – Research Report), boosting the price target to $60.00. Joshua ...

Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ETCompany ParticipantsJoe Crivelli - Vice President, ...

William Blair analyst Jake Roberge has maintained their bullish stance on VERX stock, giving a Buy rating today. Jake Roberge has given his ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

The headline numbers for Vertex (VERX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street ...

BOSTON (AP) — BOSTON (AP) — Vertex Pharmaceuticals Inc. (VRTX) on Monday reported third-quarter net income of $1.05 billion. On a per-share basis, the Boston-based company said it had net income of $4 ...

Making a noteworthy insider sell on October 9, ITEM SECOND IRR TRUST FBO JACOB J WESTPHAL ua of JEFFREY R WESTPHAL dated October , 10% Owner at Vertex VERX, is reported in the latest SEC filing.

Grant Thornton, one of America’s largest brands of professionals providing end-to-end audit, assurance, tax and advisory services, has been named the Vertex System Integrator Partner of the Year for ...

In the preceding three months, 19 analysts have released ratings for Vertex Pharmaceuticals VRTX, presenting a wide array of perspectives from bullish to bearish. The table below provides a ...